3 not yet recruiting, 1 active not recruiting, 1 completed, 1 recruiting. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Not yet recruiting 3, Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Unknown 1 |
Follow PTCL: new trials by email Literature Review of PTCL trials Research Report on PTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) SHR2554 combined with Liposomal Mitoxantrone - PTCL, First Line Treatment | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-08-01 | 2026-07-24 |
| Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide - PTCL, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 86 | 2026-03-23 | 2026-04-07 |
| Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL CD5-targeted CAR-T cells - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 30 | 2025-02-14 | 2026-05-07 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort PTX-100 - Advanced Cancer, PTCL | Phase 1 | Completed | Prescient Therapeutics, Ltd. | 25 | 2019-09-01 | 2025-09-02 |
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Volasertib, Romidepsin - PTCL, CTCL | Phase 1 | Withdrawn | Anne Beaven, MD | 2016-11-01 | 2016-12-01 |
Lymphoma, T-Cell (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
10-propargyl-10-deazaaminopterin (1) · BI 6727 (1) · Cyclophosphamide (1) · Decitabine (1) · Doxorubicin (1) · Vincristine (1) · parsaclisib (1) · pembrolizumab (1) · romidepsin (1)
Anne Beaven, MD (1) · Fudan University (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University People's Hospital (1) · Prescient Therapeutics, Ltd. (1) · Ruijin Hospital (1) · University of Virginia (1)
China (2) · Australia (1) · United States (1)
Enrica Marchi, MD, PhD (1) · Junning Cao (1) · Owen O'Connor, MD, PhD (1) · Terrence Chew, MD (1)